uniQure N.V (UQ1) - Total Assets
Based on the latest financial reports, uniQure N.V (UQ1) holds total assets worth €888.38 Million EUR (≈ $1.04 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See UQ1 net asset value for net asset value and shareholders' equity analysis.
uniQure N.V - Total Assets Trend (2016–2024)
This chart illustrates how uniQure N.V's total assets have evolved over time, based on quarterly financial data.
uniQure N.V - Asset Composition Analysis
Current Asset Composition (December 2024)
uniQure N.V's total assets of €888.38 Million consist of 70.1% current assets and 29.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 28.6% |
| Accounts Receivable | €5.88 Million | 1.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €71.04 Million | 12.8% |
| Goodwill | €22.41 Million | 4.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how uniQure N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see UQ1 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: uniQure N.V's current assets represent 70.1% of total assets in 2024, a decrease from 75.7% in 2016.
- Cash Position: Cash and equivalents constituted 28.6% of total assets in 2024, down from 69.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 4.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 12.8% of total assets.
uniQure N.V Competitors by Total Assets
Key competitors of uniQure N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
uniQure N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.12 | 6.51 | 9.47 |
| Quick Ratio | 7.12 | 6.51 | 9.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €615.56 Million | €392.87 Million | €231.58 Million |
uniQure N.V - Advanced Valuation Insights
This section examines the relationship between uniQure N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.55 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | -33.1% |
| Total Assets | €556.54 Million |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values uniQure N.V's assets at a significant premium (2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: uniQure N.V's assets decreased by 33.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for uniQure N.V (2016–2024)
The table below shows the annual total assets of uniQure N.V from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €556.54 Million ≈ $650.65 Million |
-33.08% |
| 2023-12-31 | €831.69 Million ≈ $972.33 Million |
+17.98% |
| 2022-12-31 | €704.96 Million ≈ $824.18 Million |
-12.88% |
| 2021-12-31 | €809.18 Million ≈ $946.02 Million |
+137.72% |
| 2020-12-31 | €340.39 Million ≈ $397.96 Million |
-24.13% |
| 2019-12-31 | €448.63 Million ≈ $524.50 Million |
+63.79% |
| 2018-12-31 | €273.91 Million ≈ $320.22 Million |
+30.65% |
| 2017-12-31 | €209.64 Million ≈ $245.10 Million |
+10.19% |
| 2016-12-31 | €190.26 Million ≈ $222.44 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more